-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QeZUUFwBnPLY1PKxX0PHIwJAcbJUs9Q+ElVTFFVCfQUhqqr3jga0vN3dZ+QhYyq0
 XFNeJnuy5O6Rn4K980e/wA==

<SEC-DOCUMENT>0001144204-07-047995.txt : 20070905
<SEC-HEADER>0001144204-07-047995.hdr.sgml : 20070905
<ACCEPTANCE-DATETIME>20070905160720
ACCESSION NUMBER:		0001144204-07-047995
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070905
FILED AS OF DATE:		20070905
DATE AS OF CHANGE:		20070905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		071100053

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v086972_6k.htm
<TEXT>
<html>
  <head>
    <title>

</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      September 5, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F&#160;&#160;&#160;<font style="FONT-FAMILY: Wingdings"><font style="FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-FAMILY: Wingdings"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>N/A<font style="FONT-FAMILY: Wingdings">&#160;</font></u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt="XTL Logo"></div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals to Present at the </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Arch
      Investment Conference</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, September 5, 2007 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical
      company engaged in the acquisition, development and commercialization of
      therapeutics for the treatment of unmet medical needs, particularly neuropathic
      pain and hepatitis C, today announced that Ron Bentsur, the Company&#8217;s Chief
      Executive Officer, is scheduled to present at the Arch Investment Conference.
      Mr. Bentsur will present an overview of the Company including a discussion
      of
      Bicifadine, the Company&#8217;s late-stage clinical compound for the treatment of
      neuropathic pain. Mr. Bentsur&#8217;s presentation will take place, tomorrow,
      Thursday, September 6, 2007 at 11:30 am Eastern Daylight Time, at the Warwick
      Hotel in New York City.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      live
      audio webcast of Mr. Bentsur's presentation will be available at: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">http://www.informedinvestors.com/VC/ClientPage.asp?ID=45356</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      archived version of the webcast will be available following the conclusion
      of
      the live presentation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of neuropathic pain and hepatitis C. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
      hepatitis C small molecule inhibitors. &#160;XTL also has an active in-licensing
      and acquisition program designed to identify and acquire additional drug
      candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock
      Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              September 5, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
              Bentsur</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Chief
              Executive Officer&#160;</font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0"D`P$1``(1`0,1`?_$`,T````%!0$!````````
M```````("0H+`0(#!@<%!`$``0,%`0``````````````"``"!P$$!08)`Q``
M``4#`@,$!@0)"`L``````0(#!`41!@<`""$2"3%!$Q1182(5%@IQ,A@Y@9&A
MP6(SLW9WT2,DM+76EUCPL?%"4F,U1387&1$``0($!`(%!P8*"`8#`````0(#
M`!$$!2$2!@<Q05%A<1,(@9&Q(C(4%:'!<B,6-M%"4I*RTG-4=!?A\6(S@Y,D
M&/""PD-3-"4F"?_:``P#`0`"$0,1`#\`?X%/S4]H1Y@J%![::\0D#VG)B*!:
MC^)*-+R1?D#BZP+XR5="JJ-NV#:-PWC.*I%%18(JVXEW,/RH$[3N#-F9@('>
M:@:]J2FJ+A5MV^D("G5!()XS)EYH\:NK;I*1=142[M`)('4(9(3GS8N61S46
M9MO;U;1]O:,D9((!V^`<@RD"1X*2<PE<7B%9,EG,?1<&YFAC$,/()A'CHG:/
MP[BILB<]=_\`+A&8S'J2E/#^O'C$'O;P%-Q4RA$J1)E(@S"I\.'DX<>?.'F^
MW7.-I[D,'XYSE97F4[9R5;$==$:S=T\ZP3D42+&CG8@!0%RS,;D/P"HAV:&J
M\6RIM5VJ+8^Y,L**20,,/FB9K37MWBWLUJ?52\F<OFCM0FY:`(#6O"H@%.SB
M'JU8I<4@95%(5YHR)!7)67A%P5[N;\6JI"/^Z$YNJ$3FQ(/GBOM?I?BT[ZCH
M$4E]+SP/:_2_%I?4=`A2^EYX'M?I?BTOJ.@0I?2\\6^(`&Y1K6E>(<*"-/R:
M;G:"LJ03V0BE/%2I#H,92B`CP`.SM#7MQ$-'=YO5XQDU2'Q\5033`!JH%>P`
M[`[N'=KP+BF7"MXDSPP&$,S.M"7K..<^F/H1$!*(@(CQ_P!X:B'`.'=33V^$
M\V8$\82)2PG/G/C.+CE`P4'TUTG4YDRZX<4@\8^8Q^4]"B!0`*B'I^GUCJCB
MW%HDV,>F**0ZI0=4L!L0`,54"\IA`*B%!#VN'\O=J@J&F7,BU36J/0H2,%IS
M'ICZ$Z`6@5X#3C_L#5PKC.&R`P``'5&3384#2A0-*%"+?6T/O6LO:NKF[9-E
M>X[`NK#CU>?OZW8!LP<FNRQG":1)5T!7C!^8'-N(H&7(4H!XG.(!V:WS;=K3
M=3J%%!J=`50OX((D,JN6:?*-.UP;RQ:U5EG<4EU/$=7DAG=MPZY6[F8RE&65
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M5PWNHHYCWIB-95Z@"C4H"'*0XUJ(ZR&G]J[9>:5>H=8MRN%Q45@#`-@XX@QC
M-0ZUKK+5MV>R.`4=,`$RG,GK,Y&%H-K.9NIC$=*+=#OXW'[EKS5N&XL8R4SM
MWMN290K5Q:L7&D6,CD%TM[H01,>X05`&R(@(I^7$3A[0!J(M26?1CVX5%I'3
MS:/=RL!YPF:<.($N'7/IB0;77:A:T=57:XK6JXH$VP,!VGCAR$CRX#A#:Y#K
MT]4`$4Q-O%NT]4TQ$WAVG41$@"(_]%[Q'1`HV?VY`!4EI24@3Q&)EC+&(G.N
MM<S(2XXF1(D4GICT$>NSU3G!!60W<WFLC7EYTFMKJ%`WH$Q(,Q:_AUZ?RBVY
M?3.EI<PG*<P8M7-R-8,J[IU]0>E.13+#RQC4Z\'5%0/X:^\"[D3T`>15"UDS
M4$*E$2G@Z\=>:MH=NVE=V\TVAP])'X8]&MQM9K3G2MU:.I/X)Q:3KQ=4510$
MD]X5V**CP*FFE:AS&'T`4L)S"/T:>QL[MRM:62EE3B^&4_TF'.;AZU">\"W4
MM])3_5!\^F9U>NHGG/?7M[Q9E#<K=UU6'=UT&87';[MK`IMI-KRI#X*QFT.@
ML4H#7ZIP'B.M5W#VMT?8-*UMRMK.6K8;FD\ISC.:4UEJ"[7QBFKWBIMQ821U
M$$],N42')/KCQX!4`#NH`^C0:GB%<\8)0`!&`'&,VG12&V5\;P=R$7U5(C!3
M#*<XVQ4\S?;MJ*V@1./\B,$_7`CEB"AF8N>0Y1_XZ^O1QVC:+1-5X='M=/TY
M5J!-K>?"\)9T":?)TQS:ON]6X%/XLV=OZ2L6G32[LU3J;_L+("NJ?1A#D5,]
M!.6GL@8P`/=P&E-`OD#)F"`@B<NN.DBE26$2/`&?;%5#CP"H!7@'>-=5&9P^
MJ1DYQ216O)/""P;R)O(MM[;<M3F)QF`R-'6FX7M(;>9GD)?WL5TT*EY)DF@Y
M477%(3T`$S<.[6X;?4]IK=84%'?%)1IUQ\!Y1(!"<<9G#SQ'>[3FH:;;JZ5N
MEPI6H&6"JG2)XJF)3EB?)!/NE=D/=#D#'^07>YM:^%IYE<1$[?\`C>"6@7A(
MPYE:@V06CHXRR0@0*&H;AV]NI)W^LNWECOE$SH);3]&XP%+*%)5)7/%),HB7
MPOW?<RZ6"M7N;WPJVGLK?>`@Y<>D=/#JA5],_LCPI3T]M:?GU!"BXI.9(D>B
M">FC$H([OIZXJ90_"E*"'>`U'UZ1"^[GP7#P`49DD$Q=S#2O,4/IU5M*P).2
M)ZHJ)$8#&,O=_I358;'ERL0PFH]]$RC)K(QDFT<,)&/>(D7:O63I,4G#9PBJ
M4Z:J2J9A`Q3`("`TTU!<:=#S9DY,8]$NB*.H;?94RZ)H4)1&3]<+IHR6P;<Y
M*2]M,SN=OV<I29N3';DB"HH6^]="H\FK->N!(5$7C=4RRR=/9\`Y0"G9H\-I
M=>'4^GFZ-R2KK2^HM)QFW+`CG`L:_P!,U&G[B:AC_P!1U69)'$$&?G'5!A\=
M]<^_K(Z2ER;-Q?2RVX1"4'&-FWT9VL99#"\M'*/7<NLL8XG3=P@@$*BD4:"V
M/S4X!36;CM'3O;@B^-%L6M0[THECW@/"7"1XGKB]9W">:TJ+8@K][0<@,Q[$
MN$SC/HY03;HZ=/"3Z@&[2U;7G6+PV$,;/V=XYBFDB./+O8J-.1RTM(DCRF*C
M+3:HD$HB(\R:9ZZW#=;6C6B-**6C*[=*A.5"`<4`B4P.H8X1B]`::^T]V]YJ
MI^[H,U3XF71V\,>7*)/0V-[(/9C?':]IVX^L-M$-8$EG2$+&O+;-#M&Y&R,<
MI#.&JD:HT\(E!3,F)/5QT!OO-0ESWEE135@S"YD*F>./&"I##*6/=<H+)$I=
M4<K':-M5)RTVR[?@H`%*!<.X\Y0``X!_XX`T#T:O1J#4"02JLJ,>AQ?ZT8I=
MAL^8*-,T0#^2/P1'S_,<V596/^HC(VW85HVO8\$ECNW'`0EGV[#VS$>.Y:,5
M3K^[H5FR:"L83#4_)S#7MT96P=2]4Z:-77NN._6J3)1*C@>DDF!YW6IZ6EOW
M=4S24#NTGU0!B9GEPA>CY9;!>%,E;";DFLBX=Q9?LVCE^[&B4Q>>/[3N:5(T
M([6\)L62FHE\]\!(H`!"<_*4.``&H@WUNETHM8"GHWW6V^ZF`E:DC$\Y$8QO
M^V-JMU;IU3E2TA:BN6(!Y0>OK.;;-O=H]-G<Q/VE@G#5J3\=9IEXZ=MS&%DP
MTPR6*8P<[24CH-L^:*<?KIG*8/3K4ML[Q='M=6YE^I?4@O`*!6HB1ZB2(V+6
MUHMM-I1\LLMI6A,YA(GAT&&-71N$P]2?:B)AYA^+25&A0[$$0[NWZ1XZ+7=9
MH-:%N@!F"B8^2($T(0=3TTN`?'H7$K$'ZT?PZY[\QY?28+X>QY8S:=#(:`YI
MN")M;K)(W///THF`MO/EN3,S).#)D09Q[%45':ZISC0"$)V]^NF>E6JFN\)#
MM/2-..5#EM=IT)`F5+<P!`Y@<^<<?=;5E!9_&C\5KG$M4=-=VWW%*,@E*/65
M,])'#E!Y\H]<-PK<,I$[=<`3F1(F*D7C!U<5P-YXT>_!LX4;@[CBVDA('2;K
M*$'E\;E-3CJ#;)X4%NVQBMU7>Z*WUSS:5!I13-(/`*S2.;IPE!':B\:;K5T?
MH]%:=K;K;FG"GO@%$$CFG)^+T8SCH&WKK98RR!<\+9&;+`E<33\M)MXD9I%4
MZ]JLI!RH5LW0?)R8ISK,5%S%*!CH@4*\:<1UCM;>$K5-@T^[JBPU]-<K8P)J
M;;Q<(Z4Y9@X8QE-`^-+3.I-0-:6U1;GK3<'B`%K5)"23*2LV/5"L6<LPQN&,
M-WUF=:/<7!$V1;JER&91:Z/C2S5)5NDF1DX%0&XD6*X`P&YJ"`:&32%@J-6Z
MDHM*MS8K*NL+*2H2"3CBH<9805FM]9T^B]'7'6"&_>F*2C[\!)!"TX<#Y8X1
MLAWJ0F]2RKDOB`LV9LUM;DZX@58^:<MG2[E4@@`.4S-E5DR)"7C2M=;[N[M-
M4;2Z@I;/7U(J:AZF#@4D$``\C/&<:1LCO)1[RZ;J+U34JJ8-/Y"DD*/3,2)P
MEYHT?>%U*,'[0GJ=M3A)*^\@.$5%O@^U7#(7444$^9NM-+N7"*#5)53V>3F%
M7]$*@.LAM9L3K3=3O;A;O]+9*=/K.NS"29F>0RQ,L>B,!O#XCM$;0)%!6GW[
M43JB$T[,LR<!(KZ!/#IA,T_6YS\*WOLNTHGP&8?'3ECI7X+LK/FYO$.L1@:+
M,<4N(&!04Z]]-38WX4=,Y@T[JFE3<SADFF0)ZIS^2!U'C:U9D]Z^R-6;?F]H
M)<`R],_9ZX4TV<=2C"&[Y=2V(5.4LK(C=$JBMF70LP([?`0H>.O#JMESINT2
M'X`01\4`[0X#J'-T]A-7[3N)K:]::RR.":7V@2CJ!F)`_)!(;/>(W1N[Y7;J
M+-07QN0++I&92N81S,N!'5"C_,6G:'9^;4)YAQY0068>S,9HOKJL.A%GKW8?
MP-E3IUY<?YQN9I9)<?-T;JQ]=BG(9ZSODIBH1<(R1.8`6-=:I4V"@`',4BO-
MV%XR)M5<KM0:S819B55#IRK3_8)Q)Z)=,:1N!2TM3IQUQ^6=H%2>V7*(POQ5
MQ;)G4+R+BW)S%Y0$Y53)`;E,;M'E-P`!T?[YI<B6I'WU2?(%RZ>V!$]IU009
MM9S(](!^<8Q)1_+K6SMIANGI:,M@-^24N6X9J45S1(R";=&XDL@-5_#>Q<BB
MFJJJG%QISJ$C^;@9$1$.\``7==Z]KU<ZQ>"H*;/J#'*4\B#P/7*"MV\IJ!BP
M-N4V7OW?:E(GEYO+"^^HVB18PJ]WTZ:OV8\W/9\T1P?S-'WETM_#6T_[/8Z-
M;8'[FG^(7^E`S;N_>3_#1^BJ'#7RL'W?%T?QFN[^M+ZAS?[[\)_AQZ8DO:;[
MLG]K\PA0'K??=A[H_P!R5/V@ZTO;#[_V_P#;I^>-CU[]U:SZ!B/^Z-WWDVU'
M]["_L4=&?NX/_HMR_9#YH''07WFI_P"('_7$K$'ZT?P_ZM<\>8\OI,&`/8\L
M9M.AD,E-^5INK^ZD^0["8*&(O>64(RWFQB?7!:36(B`E'M`0_-KJ[M!>&['L
M#17BL(31T5O6XD<E*`)$_-'$??.S5&H/$Q=K"R,U1679MN8XA*BD2'D./9#N
M;!NWG%F#L>6[9EBV="Q",="Q[=Z\*S1-(2;H&Y#NG$D]$A5WBRCDYAJ<1IP#
MNUS%U-K&^:JOCUWN54XZMQY2TC,0$()P`'"0CKYHW0>G=&:>9L=EI&FN[80E
M2BD$K7E$R2<2281IZT6T6Q$,7L=R=BP+"U[FM>328WLK#MDFC2<A)!8$VKMV
MU1*1,9-O+K)T7&I^0*:*OPB[G71C5#VA[FKWNVUJ?4S*)R'@1CR(Y0&7C4V>
MLSNEV=P[.V*:\T2P%I2`D+!,RK#F.,;9CG,\GFCHW93?3[DSJ;M"P[BLMZJ<
MH`8S6!E(]G%&.;F$3J':)!4W?2NL3?\`2;>C/%7;[4A`13/W!#R`.6<*)`Z)
M1F+#KG[=>#6Z7%;BA74EN6PX3Q]0H$_+&A]&F^8_&>T#<-D26`1C;*G;AN-Z
M0H\IC-HIHJZ5`!#B'!/6P>+JSNZDW0LMII#]>^TRV.TJE+Y8P'@PO*--[3:A
MOE09L404X?\`E:4KYH)OTZ\#I[Y]VF3,S9E(>X+5MR6<W;,LW2@BVGIN4DEV
M\%'+$$#@9BQ;M43'2XE.%0$*#J0M^=6L[-[86O26F5K8JWT!ES+^4$@J5RXY
MI3B(?#?HM>^N\-TUUJ8*?H*=9>0%>R0I9"4XGB)<(=??!EJ(PA+<+;D*$"5L
M#)*!!BW]S@R!/P@:`Q\,6X(>'P$O+2G=KG6Y<*[WL5:JI\5:C/,5'CQ_XQCJ
MZ;)9E49H11LFB2F64H3+T'E#3OJ2X(4V1;M+#S3A@XVM!72Y0O.$9QQ@21@9
M>)?H(S\>@1,"`G'27FE#$3"@$+0`"FND>P&K6MYMM*_;K62^]JJ=M24+5Q(*
M3EQZ00,8Y2>([2E1L/O!;=Q-(9&K75.)<0A/_D!]<$8"1F90Y'^TA$_9!^U!
MX0>0_P#4_P`?>6_Y_N[G\#DK];S7"F@,^PER_F#_`"\D>_\`?_=Y\_;E.?T<
M8Z,?S$H?Y5?S.D,OPWWF7+-EX2^E\D&F5*0"`(CPI2O-R@`>DPCPIK0PM:`E
M+>.8Q*10A:R\N4@(CY/F+NJ!&;G<M,]J&&9LK[#^$)N0-?4VU2$C.\<B)H"S
M7:(K<XA(P4,D8O(-`*5TF8>T-&#L=MTY:J8ZM=]2Z5`RA)PDUQF>TP.6YNKF
M:]X62D/U#:R9CCFX8&$R[?Z6.X:Y.G5</4):Q2Y;1AKX38L[1$AC3,EC-JR4
M:S-_$;@7Q0"/NGD9IH4J=`PJ@:@4U)#FYMAI]7_9!]P$+:(*N07,>K/IC56M
M&73X!\9;3ZX5A]&7'T09'H/=1HVQ[=7&6GD.YE8S;QG%XQM>]4G`'7C("Y5J
M-;=O!8I3`9HW8F,9%80*;F\<!'LUKF\^WR-3Z<^)4(S55(,R)<5#F!Z9QE=M
M-0&P7GW*JD*>IP6>$L<"<<3,RPQE$EVS>M7S5L\9JD<-'B"+ILX2'F26;N$B
MK(K)G`1`Q%$S@(#H%AWWO!IZD26.'D@I&W$/([QHYDRC,(A2@!0`-^/UZ]<Q
M4DSY&4>:U%223QF!$<-\S1]Y=+?PUM/^SV.C8V!^YI_B%_I0,V[OWD_PT?HJ
MAPU\K!]WQ='\9KN_K2^H<W^^_"?X<>F)+VF^[)_:_,(4!ZWWW8>Z/]R5/V@Z
MTO;#[_V_]NGYXV/7OW5K/H&(_P`Z.(E#J2;3A$W'XN$`+W_J4..C2W<=>.@J
MYA"FPG(,#QY0.6@E$:C9^K"AWXQ\JO1\\2L(\%*\>`FI00&O$>T*\*:YV!W)
MF29>B"]*SE(/##AQB\#\>PWY/Y=-+PD<!YX\Q*?XT,^,VNV#'K.13F4,0D>C
MN/LE1TJ?BFF1)\!A,81X`!1[==-=*4]0[X2BRR)U:;.3(=BHX\:J?9HO&>:A
MXRIVM1I<)^DML^D0\!**:A2F`0,40`Z9@[!*<`,00$.%!*(:YEN!:62D?WAP
M^7G'84K8>4%JQ(D1Y0(2YZP\[$QFQ/*,:_<@W=W$O`QL0B8*"Z=-YV.?+I%J
M-0$K5L<]?0&I[\,=OJ[KN]:RVGZMHE2NP`X]D##XP*VGHMF*]-0L"H?=;2V.
MGUDDCR`3A.S:5!O8KHV[EI1VB9%K/-KQ<1QCCQ5192[1N=0I1[`$YPIZ=3WN
MM64-7XO+4BC5F;144P5VY%0.FT-%6T?@PU"[4((+C52I$^8*TXQK?3HAI&X^
MFIO7@X8JAY63B;Z:L")!_.J+'B5^4A`#C500I^'5SX@:UFW>(73U7584;3C*
MR>I2T^B46'AJMS]R\-VL*.C&:M?I76P.<ULD>B-XZ"-PPS0N=+,56(6XB&AI
M7RO#Q%6/FUF2ABF$0$QDG29N8*<`"NL3XVJ-\JLUPI@3;LQ,^4R$GT1DO`'>
M&&3?;,^0+BD(6$GB9$@RZ9$"'(O,0I!$0$.(5IQ,(C0.&@9<:<<(*"`9S\D=
M)BZEA.<B8D#ATF&V_7QN*(5=X,M9-0AYT65P20-RT%0C3S[1L4AQK4HK*&`0
M"G'1V>"YNH;>O%T0DII^[",QX3D21\D<UO\`]!+FPXNQV5M055**EJ2.(!P'
MG)@[/PU,_P#QS]P^2-[W^S3XODJ#XO+Y3Q^6E*\_A<::B3XS;O\`<Q\1S?Z#
MXU/-RXRGYXG3X+5_[/\`X5W9]]^SOL\^'X(X-U[NI9&;&]KBU@V7<[-CG_.Z
M3NUK.9MWK="5MVVE$13N2[#\ROC,%&C-P'E#F*`**%,`=FH]VGT*YK*^!#^5
M%K9&968R)ZL>,3]K;4+UFL9]T255B\.!,@>SM$NV&'_3TV?7EU#-V5DX-MUT
MG(M9F9+=65[E<.^<L=9;>0"1NIX\<%.*@R$VW!RB@:H5<'"E>S19ZOU50:+L
M+CR5HSMM]TVA)F292!,#UIG3=7J*](2ZAQ`*LRB<.!F9'I&!Z8E2H?!.,[>P
MFQV^1MLQJ6+&=AIXW"W#LVIF2MNDA0A#>80\($572R!?$.IR\QEO;^MQT`:;
MD_4W==Y6M?OA>[P&9XS\\H+=NWT[5O%M0!W"6\@'5*7GYQ%X]5#8I<73TW8W
MEBZ30*UQY/NU+OPU-^()6S^U'CCQV;!NX.<H#(6Z(II+``B)#B&C_P!O=:46
MK-*)-6\VFO;3D*3@)C`S!X]1@3M66*KLE]4.Z66"<P*>@XC'KGCT0[X^7-ZH
M\3N>PPSV@97NQ)_G["<*J2VWCY^@N^O[&;`"$8O$%A.9:1EH!/F!Z;VN5,Z=
M:!30M;P:+8T]?OBE"4&@<,_5/!1X^0Q-FV^J7KE3"WUB5BK2F8F"!(<L>C&'
M/`%.-`$2T*/KK3UB(ZB%80I)R\3C$F/36L9)9.<1OOS-;MHCU,)9-=R@BH.-
M+5,4BJR:9A*#!@',!3&*:G'MT9NPKC5/I%1J7VT-]^H@'`XGM@:]V*>H7?R\
M&UJ;[M(F`>("H<-_*MKIK]/6ZCHJI*E#--WE`Z9RJ$$0>+A2I1$*AJ(-^WF'
M=;A;"PMON!B(DG:MIQO3I;4E25YYR5V0H'UP%`2Z86Z8ZQB)IDLDXF.<P$*7
MVQ$1,8P@`!K3=M"E.N[:YF"4>\)F3T1GM=$_91\*25+4F1`ZXC!<39AN["UZ
MVKE'&-XFM*_+24*]MVY8QRS!_%NC)E`R[;QP72`X@`?6*(<-'K=FK->:1ZVW
M$LNTKF!,\988<8%*FJ+G:ZX5-`AQ#B%3Q!/K`G'E"C@]<WJ=B83?;/R'4W$:
M.[;#\@1```?1PUH*=L-M0)>[L$=HC85ZWUPMPN!YX*/0DR@#US>IX`"(;T,B
M5IP_IEN=O=_VC2.V&VI!`IF)RZ1"&M]<@@]^_P`?R3!S]N60\Y[JYJP[]D+M
M<Y"W`7I(IS2<[)OF24O-W%'G(JU$%&Z:*7G#&-[`%)Q'NT1UD>T;H[:A-!?'
M`S95TIIW$@YE)0<)B7/'C'/;<&WZNU!OS4U5D86Y?#4IJ!@0%+1C+^B'1N(>
MMMB.W[4C[0W%VC=]CY0M9!.!N9LRC%9`CF5B_P"A+KBP22\['\Y40,(*\35J
M'`0T$^H?"WJBXU*KMH*HI:O3U2HK965@$!6(2H3Y0;^EO&=I.@MXM6XM%6T&
MH:63;H#94E10`,PD,)RX<83WW8;H,I]4[)=G8/V_V/,CCZ#FP721%5-859!V
M8S=:X[I?MB>6AHYM%JG%--QRCST*`B8>,[;8:!T[X=;+4ZSU]7,'5):(2AM0
M4D)RSR`<U%7,=D#_`+N[I:C\46HJ+1N@**H&G&Z@$K6DHX^KF5.6&7IA:K/.
M&HC;YTP<H8JC?!$ELX=<)RBZ=`1=3*KJ+/+/"&J`<KAYS&"O&@Z$K2NJW=9;
M^6[4Y)#E7<@4!1P"!,)!Z))@SM<:(:V_\,EVTK0#,JGM2@KGF6HHSREQQ&$%
M/Z$247*[?,M,E/`?L75]2#1T@;D60426(*2J*P!S%$I@-0:]VI6\9]4A>X-"
MY1*S/,4;1FDXYDF<1%X%*(G;RZ,5S93WU0`L*$DD9)8`]I@A.4\:9YZ5F[*1
MS19-NOYW#\U.2*K)XR`ZL-(6M+*BY<P=Q+D`S>)>M5%E?`,L8I0$0&@ZEVT7
MO1OB1VVI=*W:J12ZNIFQZJO5]=*<H5CB4F0X<X@2]:1U[X6-VW=866G76:->
M<40L>M-IPS*5`<%)GAA*%,#]=;:N2T$Y<T!>871Y0J@VJ#,`;^;\,!,W"XA1
M]UBW!3AXGU>74`_[0]UA<C39Z+W+O)!T/)RA$Y3E/C+&4$\?')M/\*-0VU7*
MN:4B;'<JF5D<C*4@><)DV)BS/'5BW3(YDNBWI&VL.1LS&!(2L@"Q(>/M.'4!
M5O!VNL)2(3$D^!),7!VYC$Y@&H:(2_Z@T=X:MME:4M=2W5ZOJ`2L(Q]=0*9S
M&(2)P,MCT5KWQ2;NC6E^IW*32*%)""J8`;000`#S,L8=B_`]O?!?P#[L;_"W
MP_\`#?NKPR^7]U>4\KY;P^SD\/NUSH^(U/Q#XM,^]][WD^>;-FCJQ\'HO@WP
M'(GW#N.YERRY<O9PCP+MPSBB_P!\UDK]Q;CN^)!F@+9K(7A9ELW,_:MQ`0\!
ML\G(Q^X01H(U*0P%]6FTM?<Z`$4-2ZU/CE4I,_S2(NG[=0U/]^A*_I`'T@Q2
MT\,8GL.2<RMBXLQW8\@Z;$:.9"T+*M>VI!TV34%4C99["1C%RJW(H/,!#&$M
M>[2K*^X5K815ONN@&<EJ4K](F&T]!1TKOO%.TA#TI3"4C#R`1TXI3`%!XAZZ
M5IZ!U9J2%24!)47RR#(CC..?7KB;&>15F#J_<<6%?#B*342C5KPL^W+G69)+
M&*=9%FK.1KY1HFJ8H"8$Q*!A#CJ]IZZMHD%-&\ZV"<<JE)G^:1%D_14M4^%U
M+:%I`YI!](,>=:V#<,V/-)W%9.(,8V=/H(+M6\[:]A6G;TNBU=E*5VV2DH>)
M9ODV[HA`!1,%`(H``!@&FF/7&YUP+5>\ZXSRS+4K](F&M6ZBI5=[2-MH>Z0E
M(]`$=0*4X_6*``(C6@_EU;(GE(.'1V1>Y&Y3_&^>.873A'#]\ROOV]L2XRO"
M:%(&YI>Z+#M2X94Z!!`$T32,Q$O'HI%`H4+S\H4U<IN-TI&.ZH7W4#H"U)'F
M!`BS>H*2K,ZMIM?:E)](,;+:EAV=848:'L.S[6LJ)47.Y4B;4@(BVXX[E01%
M1R=E"M&34RYQ&IC"7F-WCKR=J*JJJ>_K'%N'+*:B5'SDDRBZIV*:F1W;*$H1
MU``>881ZMPVY!77$.X*Y82'N*%D"`D_AY^,93$4\2[R.HZ00<LW)?T5"&+JB
M'7F7$NL*4EQ)P()!\XD1"<;:>3W;R0IOH(F/ECD9=L6W$H<OV><'#3A[.*+`
M`*4H%`^'^&L@J]7P^S65`_Q'/UHL%6NU@^K2LD?01^"*_9CVX?Y>,'_X46!_
M=[3?C-]_?:C_`#'/UHI\,MO[HQ^8C]6*?9CVX?Y>,'_X46!_=[2^,W[]]J/\
MQS]:%\,MO[HQ^8C]6-BA<)XEMATQ>6QB['=N.HT_/'N8.RK9BEF!^Y1B=C&(
M&:*%[C$$HAKU?OEZK*55)6U=0ZTKB%.+(\Q,8ZGTKIRDN*;NQ04R;D,.\#:`
MK'CZP$XT?(>TW;QE=\I*Y!Q%9EQ2JJAE%9%6);,GZYS``&5=O(XK5=TH8`XB
MH8XZS5DW$USIAD4MCN-2U2@8("_5'6`9R\DHP=]VJV[U'5*K;S::.HJUF:E*
M0`3VRE/RX]<=`L'$6.L6L0CL=V-:UGM@1(V-[BAHY@Y60)02D=OD&Y'CR@A7
M^<.;6%NVH+_J&H557ZK>J5JG@M1(GV3D/)&>L>D],Z;9[BP4%-1I`XMH2#YP
M)R\L;I*P[&;8.8J7C6,I&O41;NX^0:MWC)RD(@(I.6CDBC==$1+42F*(5`.&
ML6TX_2+0[1*+;[9FE:3)23U$8CR1EZFD8N%&JDN#:7:=8DM"@"E0ZP<#'D6Q
M8]K6:V79VK;%NVPT=*F7<M;=AXZ&;N%C\3*K(QS9LFHJ(]IC`(ZNZRXW&XO"
MHN#[KSR1(%:E*,NU1)BRMU@LMGIS2VBF:IF'#-:6TI2)]@`CT9VW(>Y(Y>*G
MH:*G(QP6B\9,,6TDQ<4#AXC5XFLW,/K$NK:EJJ^BJ/>J)Y3-1^4@E)EVB4>]
M=:K;=:<4-S9;?HOR5I"AVX@P6H-C6U'WN,\."[$"346\RHH6-+Y?Q:\W!@8?
M(`3F'ZH)@7U4UO+>Z6XS=+[F+Q5]QT9SZ>,1PK8S:85AKF[)1IJ2J>8(D9]/
M1!EH*VX2V(MM"VY#Q<#$M0Y6\9#L6D8P0`:5\)HR210(8:<1`O'6D5=157&L
M-=<'G'J@\2M142>TDQ)5);J"W4J:"W,ML4:1[*`$CS"4>_ZM>47DL)<HL#GK
MQ[/P:45B_2A10U:>SVU]7Y]*%`"M./;I0HKI0H&E"@:4*!I0H&E"@:4*!I0H
>&E"@:4*!I0H&E"@:4*!I0H&E"@:4*!I0H&E"C__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
